These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 26303327)
1. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy. Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of anti-tumor activity of Newcastle disease virus by the synergistic effect of cytosine deaminase. Lv Z; Zhang TY; Yin JC; Wang H; Sun T; Chen LQ; Bai FL; Wu W; Ren GP; Li DS Asian Pac J Cancer Prev; 2013; 14(12):7489-96. PubMed ID: 24460323 [TBL] [Abstract][Full Text] [Related]
3. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862 [TBL] [Abstract][Full Text] [Related]
4. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899 [TBL] [Abstract][Full Text] [Related]
5. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy. He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362 [TBL] [Abstract][Full Text] [Related]
6. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy. Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497 [TBL] [Abstract][Full Text] [Related]
7. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Rodriguez-Madoz JR; Zabala M; Alfaro M; Prieto J; Kramer MG; Smerdou C Hum Gene Ther; 2014 Feb; 25(2):132-43. PubMed ID: 24219025 [TBL] [Abstract][Full Text] [Related]
8. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
10. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066 [TBL] [Abstract][Full Text] [Related]
11. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy. Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604 [TBL] [Abstract][Full Text] [Related]
12. Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses. Liu T; Zhang Y; Cao Y; Jiang S; Sun R; Yin J; Gao Z; Ren G; Wang Z; Yu Q; Sui G; Sun X; Sun W; Xiao W; Li D Gene Ther; 2021 Dec; 28(12):697-717. PubMed ID: 32409746 [TBL] [Abstract][Full Text] [Related]
14. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect. Pan Z; He J; Rasoul LM; Liu Y; Che R; Ding Y; Guo X; Yang J; Zou D; Zhang H; Li D; Cao H PLoS One; 2016; 11(10):e0164723. PubMed ID: 27736965 [TBL] [Abstract][Full Text] [Related]
15. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027 [TBL] [Abstract][Full Text] [Related]
16. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307 [TBL] [Abstract][Full Text] [Related]
17. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model. Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432 [TBL] [Abstract][Full Text] [Related]